Literature DB >> 26700603

Minimizing the uncertainties regarding the effects of delaying radiotherapy for Glioblastoma: A systematic review and meta-analysis.

Luiz Victor Maia Loureiro1, Elivane da Silva Victor2, Donato Callegaro-Filho2, Ludmila de Oliveira Koch2, Lucíola de Barros Pontes3, Eduardo Weltman4, Edna Terezinha Rother2, Suzana Maria Fleury Malheiros5.   

Abstract

BACKGROUND AND
PURPOSE: Previous studies have provided no clear conclusions regarding the effects of delaying radiotherapy (RT) in GBM patients. We present a systematic review and meta-analysis to address the effect of delayed RT on the overall survival (OS) of GBM patients.
METHODS: A systematic search retrieved 19 retrospective studies published between 1975 and 2014 reporting on the waiting time (WT) to RT for GBM patients. The meta-analysis was performed by converting WT to RT studies intervals into a regression coefficient (β) and standard error expressing the effect size on OS per week of delay.
RESULTS: Data required to calculate the effect size on OS per week of delay were available for 12 studies (5212 patients). A non-adjusted model and a meta-regression model based on well-recognized prognostic factors were performed. No association between WT to RT, per week of delay, and OS was found (HR=0.98; 95% CI 0.90-1.08; p=0.70). The meta-regression adjusted for prognostic factors weighted by the inverse-variance (1/SE(2)) showed no clear evidence of the effect of WT to RT, per week of delay, on OS.
CONCLUSIONS: This meta-analysis, despite limitations, provided no evidence of a true effect on OS by delaying RT in GBM patients.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Delay; Glioblastoma; Prognosis; Radiotherapy; Survival; Waiting time

Mesh:

Year:  2015        PMID: 26700603     DOI: 10.1016/j.radonc.2015.11.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.

Authors:  Chan Woo Wee; Eunji Kim; Tae Min Kim; Chul-Kee Park; Jin Wook Kim; Seung Hong Choi; Roh-Eul Yoo; Soon-Tae Lee; Il Han Kim
Journal:  J Neurooncol       Date:  2017-05-25       Impact factor: 4.130

2.  Early initiation of chemoradiation may not influence survival of high-grade gliomas.

Authors:  Luiz Victor Maia Loureiro; Suzana Maria Fleury Malheiros
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

3.  The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma.

Authors:  Vanessa Montes Santos; Gustavo Nader Marta; Marcella Coelho Mesquita; Rossana Veronica Mendoza Lopez; Edla Renata Cavalcante; Olavo Feher
Journal:  J Neurooncol       Date:  2019-03-08       Impact factor: 4.130

4.  Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.

Authors:  C Balaña; A Estival; I Teruel; M Hardy-Werbin; J Sepulveda; E Pineda; M Martinez-García; O Gallego; R Luque; M Gil-Gil; C Mesia; S Del Barco; A Herrero; A Berrocal; P Perez-Segura; R De Las Penas; J Marruecos; R Fuentes; G Reynes; J M Velarde; A Cardona; E Verger; C Panciroli; S Villà
Journal:  Clin Transl Oncol       Date:  2018-05-08       Impact factor: 3.405

5.  Treatments of gliosarcoma of the brain: a systematic review and meta-analysis.

Authors:  Xing Wang; Jiao Jiang; Meixi Liu; Chao You
Journal:  Acta Neurol Belg       Date:  2020-11-06       Impact factor: 2.396

6.  Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Authors:  Supriya Mallick; Haresh Kunhiparambath; Subhash Gupta; Rony Benson; Seema Sharma; M A Laviraj; Ashish Datt Upadhyay; Pramod Kumar Julka; Dayanand Sharma; Goura Kishor Rath
Journal:  J Neurooncol       Date:  2018-06-23       Impact factor: 4.130

7.  Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.

Authors:  Andreas Merkel; Dorothea Soeldner; Christina Wendl; Dilek Urkan; Joji B Kuramatsu; Corinna Seliger; Martin Proescholdt; Ilker Y Eyupoglu; Peter Hau; Martin Uhl
Journal:  J Neurooncol       Date:  2017-01-18       Impact factor: 4.130

8.  Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom.

Authors:  Ruichong Ma; Aswin Chari; Paul M Brennan; Andrew Alalade; Ian Anderson; Anna Solth; Hani J Marcus; Colin Watts
Journal:  Neurooncol Pract       Date:  2017-09-27

9.  Survival after radiation therapy for high-grade glioma.

Authors:  Joana Spaggiari Marra; Guilherme Paulão Mendes; Gerson Hiroshi Yoshinari; Flávio da Silva Guimarães; Suleimy Cristina Mazin; Harley Francisco de Oliveira
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-11

10.  Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients.

Authors:  Maochen Zhang; Fei Xu; Weiqiong Ni; Weixiang Qi; Weiguo Cao; Cheng Xu; Jiayi Chen; Yunsheng Gao
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.